NRX Pharmaceuticals (NRXP) Depreciation & Amortization - Total (2024 - 2026)

NRX Pharmaceuticals (NRXP) has reported Depreciation & Amortization - Total for 3 consecutive years, with $100000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization - Total changed 0.0% year-over-year to $100000.0 in Q2 2026; TTM through Jun 2026 was -$1.9 million, a 114.94% decrease from a year earlier, with the FY2025 full-year figure at $10000.0, changed 0.0% from the prior year.
• Depreciation & Amortization - Total was $100000.0 for Q2 2026 at NRX Pharmaceuticals, up from $20000.0 in the prior quarter.
• Over five years, Depreciation & Amortization - Total peaked at $2.0 million in Q3 2025 and troughed at -$4.0 million in Q4 2025.
• A 3-year average of -$391428.6 and a median of $20000.0 in 2025 frame the typical range for Depreciation & Amortization - Total.
• Across the five-year window, Depreciation & Amortization - Total slumped 303.03% in 2025 and changed 0.0% in 2026, its largest moves.
• Over 3 years, Depreciation & Amortization - Total stood at -$990000.0 in 2024, then tumbled by 303.03% to -$4.0 million in 2025, then jumped by 102.51% to $100000.0 in 2026.
• The last three Depreciation & Amortization - Total figures came in at $100000.0 (Q2 2026), $20000.0 (Q1 2026), and -$4.0 million (Q4 2025), per Business Quant data.